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Abstract
Background: Opioids exert a profound influence on immunomodulation and enhance HIV infection and replication.
However, the mechanism(s) of their action remains to be determined. We thus investigated the impact of morphine on the
intracellular innate antiviral immunity.
Methodology/Principal Findings: Seven-day-cultured macrophages were infected with equal amounts of cell-free HIV Bal
or SIV DeltaB670 for 2 h at 37uC after 24 h of treatment with or without morphine. Effect of morphine on HIV/SIV infection
and replication was evaluated by HIV/SIV RT activity assay and indirect immunofluorescence for HIV p24 or SIV p28 antigen.
The mRNA expression of cellular factors suppressed or induced by morphine treatment was analyzed by the real-time RT-
PCR. We demonstrated that morphine treatment of human blood monocyte-derived macrophages significantly inhibited
the expression of interferons (IFN-a, IFN-b and IFN-l) and IFN-inducible genes (APOBEC3C/3F/3G and 3H). The further
experiments showed that morphine suppressed the expression of several key elements (RIG-I and IRF-7) in IFN signaling
pathway. In addition, morphine treatment induced the expression of suppressor of cytokine signaling protein-1, 2, 3 (SOCS-
1, 2, 3) and protein inhibitors of activated STAT-1, 3, X, Y (PIAS-1, 3, X, Y), the key negative regulators of IFN signaling
pathway.
Conclusions: These findings indicate that morphine impairs intracellular innate antiviral mechanism(s) in macrophages,
contributing to cell susceptibility to AIDS virus infection.
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Introduction
Injection drug users (IDUs) are at a significant high risk for
aquiring HIV infection and contribute to the spread of the virus
[1,2]. Several early studies indicated that intravenous use of
opiates influences the outcome of HIV infection [1,2,3,4,5]. IDUs
frequently involve the abuse of heroin, the most common abused
opiate. Heroin injection increased the risk of acquiring HIV [6]
and progression to AIDS [3]. However, because of the extreme
complexity of opiate addition and/or HIV infection, it has been
extremely difficult to compare different clinical and epidemiolog-
ical findings in studying the impact of opiate abuse on HIV disease
progression [7]. In contrast, laboratory in vitro studies have yielded
relatively agreeable data, showing that morphine, the active
metabolite of heroin, enhances susceptibility of the immune cells to
HIV infection. Peterson et al. first reported that morphine
enhances HIV replication in human PBMC coculture system
[8]. Several studies [9,10,11,12,13,14,15] showed that morphine
could activate mu opioid receptors of human immune cells
(macrophages, T lymphocytes, microglia) and up-regulate the
expression of CCR5 and CXCR4, the key HIV entry coreceptors.
Morphine-mediated induction of CCR5 and CXCR4 was
associated with increased HIV infection of macrophages [10,16].
Morphine also enhanced simian immunodeficiency virus (SIV)
infection and replication in both in vivo and in vitro systems.
Morphine treatment increased SIV replication in CEM6174 cells
[17]. Injection with morphine enhanced SIV replication in Rhesus
Macaques [18]. Induction of CCR5 expression in monkey
peripheral mononuclear cells by morphine contributes to en-
hanced SIV replication [14]. However, it has also been reported
that morphine treatment slowed SIV disease progression
[7,19,20].
Although the role of opiates in promoting HIV disease
progression is still debatable, overwhelming evidence indicates
that heroin and other opiate derived substances affect both
adaptive and innate immunity [20,21,22,23]. Innate immunity is
the first line of the defense mechanism against viral infections.
Interferons (IFNs) are key players in host innate immunity, as they
possess antiviral activity against a variety of viruses [24], including
HIV [25,26]. While both type I IFNs (IFN-a,- b,- v,- k,- e,- t,- d
and -n subtypes) and type II IFN (IFN-c) have been known for
decades as the antiviral cytokines, a novel class of cytokines
(interleukin-28/29) was recently discovered and named as type III
IFNs (also called IFN-l) [27]. Although IFN-l exerts its action
through a receptor complex distinct from that for the type I IFNs
[28,29,30,31], IFN-l shares a number of common biological
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potent antiviral activity against viral infections [32,33,34],
including HIV [26]. Given the critical role of IFNs control of
HIV replication, it is of importance to determine the specific
impact of opiates on IFN signaling pathway and the mechanisms
responsible for the actions.
Materials and Methods
Cell culture
Peripheral blood was purchased from the Center for AIDS
Research at the University of Pennsylvania. The protocol used to
isolate blood from donors, purify the blood components, and
distribute this material to the investigators was approved by the
IRB of the Center for AIDS Research. These blood samples were
screened for all normal blood-borne pathogens and certified to be
pathogen free. Monocytes were purified from peripheral blood of
three healthy adult donors according to our previously described
technique [35]. Freshly isolated monocytes were cultured in 48-
well culture plates at a density of 2.5610
5 cells/well in Dulbecco
modified Eagle medium (DMEM) containing 10% fetal calf serum.
Macrophages refer to 7-day-cultured monocytes in vitro.
Reagents
Morphine sulfate was obtained from National Institute on Drug
Abuse (Rockville, MD). Naltrexone was obtained from Sigma (St
Louis, MO). Mouse anti-HIV p24 monoclonal obtained from the
AIDS Research and Reference Reagent Program (NIH, Bethesda,
MD). Mouse anti-SIV p28 monoclonal antibody was purchased
from Fitzgerald Industries (Acton, MA). Alexa Fluor 488 goat anti-
mouse IgG and Hoechst 33342 were purchased from Invitrogen
(Carlsbad, CA).
Morphine and/or naltrexone treatment
Seven-day-cultured macrophages (2.5610
5cells/well) were
treated with or without morphine at different concentrations
(10
212 to 10
28 M) for different time points (3–24 h). To
investigate whether naltrexone antagonizes the morphine action,
we used naltrexone (10
28 M) to treat macrophages for 1 h
followed by morphine treatment. There were no cytotoxic effects
of morphine and naltrexone treatment on macrophages as
demonstrated by trypan blue dye staining (data not shown).
Infection of macrophages with HIV Bal strain or SIV
DeltaB670 strain
HIV Bal strain and SIV DeltaB670 strain were obtained from the
AIDS Research and Reference Reagent Program (NIH, Bethesda,
MD). Macrophages were infected with equal amounts of cell-free
HIV Bal (p24 20 ng/10
6 cells) or SIV DeltaB670 (p28 20 ng/10
6
cells) for 2 h at 37uC after 24 h of treatment with or without
morphine. The cells were then washed three times with Dulbecco’s
modified Eagle’s medium to remove unabsorbed virus, and fresh
media containing morphine and/or naltrexone were added to the
cell cultures. The final wash was tested for HIV/SIV reverse
transcriptase (RT) activity and shown to be free of residual inocula.
Untreated cells served as a control. Culture supernatants were
collected for HIV/SIV RT activity assay at days 3, 6, 9, 12 and 15
after infection.
HIV/SIV RT assay
HIV and SIV RT activity was determined based on the
technique of [36] with modifications [37]. In brief, 10 ml of culture
supernatants from macrophages infected with or without HIV/
SIV was added to a cocktail containing poly(A), oligo(dT)
(Amersham Biosciences, Inc., Piscataway, NJ), MgCl2, and
[32P]dTTP (Amersham Biosciences, Inc.) and incubated for
20 h at 37uC. Then, 30 ml of the cocktail was spotted onto
DE81 paper (Whatman Internatianl Ltd, England), dried and
washed five times with 26 saline-sodium citrate buffer and once
with 95% ethanol. The filter paper was then air-dried.
Radioactivity was counted in a liquid scintillation counter
(PerkinElmer Life Sciences, Boston, MA).
RNA extraction and real-time RT-PCR
Total RNA from macrophages was extracted with Tri-Reagent
(Molecular Research Center, Cincinnati, OH) as previously
described [38]. Total RNA (1 mg) was subjected to RT using the
RT system (Promega, Madison, WI) with random primers for 1 h
at 42uC. The reaction was terminated by incubating the reaction
mixture at 99uC for 5 min, and the mixture was then kept at 4uC.
The resulting cDNA was then used as a template for real-time
PCR quantification. Real-time PCR was performed with 1/10 of
the cDNA with the iQ SYBR Green Supermix (Bio-Rad
Laboratories, Hercules, CA) as previously described [39]. The
amplified products were visualized and analyzed using the
software MyiQ provided with the thermocycler (iCycler iQ real
time PCR detection system; Bio-Rad Laboratories). The oligonu-
cleotide primers were synthesized by Integrated DNA Technol-
ogies, Inc. (Coralville, IA) and sequences will be available upon
request. The cDNA was amplified by PCR and the products were
measured using SYBR green I (Bio-Rad Laboratories, Inc.,
Hercules, CA). The data were normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and presented as the change
in induction relative to that of untreated control cells.
Immunofluorescence assay
The macrophages infected with HIV Bal or SIV DeltaB670
strain were cultured on glass coverslips at adensity of 2.5610
5/well
in 48-well plates. The macrophages were washed with 16 cold
PBS (with Ca
2+ and Mg
2+) twice. Cells were fixed at 4uCi n4 %
paraformaldehyde-4% sucrose in PBS for 20 min followed by
0.2% Triton X-100 for additional 10 min. Cells were blocked in
Block Solution (Pierce, Rockford, IL) for 1 h at room temperature.
To examine expression of HIV p24 or SIV p28, the fixed cells
were stained with mouse anti-HIV p24 (1:500) or mouse anti-SIV
p28 monoclonal antibody (1:500). After washing five times with
16PBS, the cells were incubated with fluorescein isothiocyanate-
conjugated goat anti-mouse IgG antibody (green, 1:100) for 1 h.
The cells were then mounted on a glass coverslip in mounting
media (Biomeda, Foster City, CA) and viewed with a fluorescence
microscopy (Zeiss, Jena, Germany). Hoechst 33342 was used for
nuclei staining.
Statistical analysis
Student’s t-test was used to evaluate the significance of
difference between groups, and multiple comparisons were
performed by regression analysis and one-way analysis of variance.
P values of less than 0.05 were considered significant. All data are
presented as mean 6 SD. Statistical analyses were performed with
SPSS 11.5 for Windows. Statistical significance was defined as
P,0.05.
Results
Morphine enhances AIDS virus infection of macrophages
We first determined the effect of morphine on AIDS virus (HIV
and SIV) infection of macrophages. The addition of morphine to
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were incubated with or without morphine (10
210 M) for 24 h before HIV or SIV infection. An opioid receptor antagonist, naltrexone (10
28 M) was
added to macrophage cultures 1 h before morphine (10
210 M) treatment. HIV or SIV RT activity in culture supernatant was determined at day 6
postinfection. Data are expressed as HIV (A) and SIV (B) RT activity in morphine-treated cells (percentage of control) to those in untreated cells,
morphine-treated cells plus naltrexone versus morphine only. The results represent the mean 6 SD of three experiments using cells from three
different donors. Statistical analysis was performed using one-way analysis of variance, and significance is shown with * P,0.05 (morphine vs control
or morphine vs morphine + naltrexone).
doi:10.1371/journal.pone.0031167.g001
Figure 2. Effects of morphine on HIV p24 protein or SIV p28 protein expression in macrophages. Seven-day-cultured macrophages were
treated with or without morphine (10
210 M) for 24 h and then incubated with HIV Bal strain or SIV DeltaB670 strain for 2 h in the presence or absence
of morphine (10
210 M). HIV p24 (A) or SIV p28 (B) protein expression in macrophages at day 15 postinfection was determined by immunofluoresence
staining with antibodies against HIV p24 or SIV p28 protein (green). The nuclei were stained with Hoechst 33342 (blue) (magnification, 1006; scale
bar: 100 mm).
doi:10.1371/journal.pone.0031167.g002
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and viral protein expression (Fig. 2A). Similarly, morphine
treatment enhanced SIV DeltaB670 replication (Fig. 1B) and viral
protein expression in macrophages (Fig. 2B). These effects of
morphine on HIV or SIV were time- and dose-dependent (Fig. 3)
and could be abrogated by naltrexone (Fig. 1A and 1B).
Morphine suppresses intracellular type I and type III IFN
expression
IFNs play a key role in host cell innate immunity against viral
infections, including HIV. We then examined whether mor-
phine has the ability to inhibit intracellular IFN gene expression
in macrophages. Morphine treatment significantly suppressed
IFN-a ( F i g .4 A ) ,I F N - b (Fig. 4B) and IFN-l (Fig. 4C) expression
in macrophages. These negative effects of morphine on IFNs
could be abrogated by naltrexone treatment of macrophages
(Fig. 4). Naltrexone alone had little effect on the IFN expression
(Fig. 4).
Morphine suppresses RIG-I, IFN regulatory factors and
APOBEC3
Since TLR and RIG-I play the key roles in IFN-mediated
innate immunity against viral infections, we examined whether
morphine treatment has the ability to modulate TLR or RIG-I
expression. Morphine treatment of macrophages had little effect
on TLR-3 or TLR-7 expression (Fig. 5A). In contrast, morphine
inhibited RIG-I expression in macrophages (Fig. 5A). We also
examined the effect of morphine on IRF expression in macro-
phages, as IRFs have a crucial role in the regulation of IFNs
[40,41,42]. Morphine treatment resulted in a significant decrease
of IRF-7 expression in macrophages (Fig. 5B). However, morphine
had little effect on the expression of IRF-3 and IRF-5 in
macrophages (Fig. 5B). Because some of the apolipoprotein B
mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3)
family members have been shown to inhibit the expression of HIV
or SIV [43,44], we thus examined whether morphine has the
ability to inhibit APOBEC3 gene expression in macrophages.
Morphine-treated macrophages expressed the lower levels of
several members (3C, 3F, 3G and 3H) of APOBEC3 family than
untreated macrophages (Fig. 6). Morphine had little effect on
APOBEC3B expression (Fig. 6).
Morphine induces SOCS and PIAS
To further investigate the mechanism(s) involved in the
morphine action on HIV and IFN signaling pathway, we
investigated effects of morphine on the negative regulatory factors
of IFN pathway. SOCS and PIAS are two major families of
negative regulators of signal transduction induced by cytokines
[45,46]. SOCS members form a classical negative feedback loop
with key actions involving in inhibition of the JAK-STAT
signaling cascade, while PIASs are specific inhibitors of STAT
signaling. As demonstrated in Figure 7, morphine treatment
induced the expression of SOCS-1, 2, 3 and PIAS1, 3, X, Y in
macrophages.
Figure 3. Dose-dependent and time-course effects of morphine on AIDS virus replication. A and C: Dose-dependent effect of morphine
on HIV or SIV replication. Seven-day-cultured macrophages were treated with or without morphine at indicated concentrations for 24 h and then
incubated with HIV Bal or SIV DeltaB670 strain for 2 h in the presence or absence of morphine. Day 6 culture supernatant was collected for HIV (A) or
SIV (C) RT assay. B and D: Time-course effect of morphine on HIV or SIV. Seven-day-cultured macrophages were treated with or without morphine
(10
210 M) for 24 h prior to infection with HIV Bal strain or SIV DeltaB670 strain for 2 h and then cultured for 15 days. HIV (B) or SIV (D) RT activity was
determined in cultured supernatants at indicated time points postinfection. Data are expressed as HIV or SIV RT activity in morphine-treated cells
(percentage of control) compared with those in untreated cells. The results represent the mean 6 SD of three independent experiments using
macrophages from three different donors. Statistical analysis was performed by one-way analysis of variance (A, C) or Student’s t-test (B, D), and
significance is shown morphine versus control with * (P,0.05) and ** (P,0.01).
doi:10.1371/journal.pone.0031167.g003
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Given immunomodulation and immunocompromising effect of
opiates, abuse of opiates has been suggested as a cofactor in
promoting HIV disease progression. However, much remain to
be learned about the mechanisms of opiate-mediated broad
influence on host immunity related to control of viral replication.
In this study, we showed that morphine significantly inhibited
endogenous type I (IFN-a/b) and III (IFN-l1) IFN expression
(Fig. 4), which was associated with increased susceptibility of
macrophages to HIV and SIV infection and enhanced virus
replication. This morphine effect is specific through the opioid
receptor, as the suppression of IFN expression by morphine could
be abrogated by naltrexone (Fig. 4). These findings support the
earlier reports showing that morphine suppresses Sendai virus-
induced IFN-a production by peripheral blood mononuclear cells
and monocytes [47,48]. Our earlier study also showed that
morphine inhibited endogenous IFN-a expression and enhanced
complete hepatitis C virus replication in human hepatocytes [49].
A novel finding of this study is that morphine inhibited IFN-l
expression in macrophages (Fig. 4). IFN-l has been shown to
inhibit replication of a number of viruses, including HIV [26].
Thus, the finding that morphine inhibited endogenous IFN-l
expression in macrophages provides a sound mechanism for the
morphine action on HIV or SIV.
In order to further investigate the mechanism(s) responsible for
the action of morphine, we examined the effect of morphine on
Figure 4. Effect of naltrexone on morphine-mediated down-
regulation of IFNs expression. Seven-day-cultured macrophages
were incubated with or without naltrexone (10
28 M) for 1 h before
treatment with or without morphine (10
210 M) for 3 h. Cellular RNA
was subject to the real-time RT-PCR for IFN-a (A), IFN-b (B) and IFN-l1
mRNA (C). Data are expressed as mRNA levels in morphine treated cells
(percentage of control) those untreated cells and morphine treated
cells. The results represent the mean 6 SD of three independent
experiments. Statistical analysis was performed using one-way analysis
of variance, and significance is shown with *P,0.05 (morphine vs
control or morphine vs morphine + naltrexone).
doi:10.1371/journal.pone.0031167.g004
Figure 5. Effect of morphine on TLRs, RIG-I (A) and IRFs (B)
expression. Seven-day-cultured macrophages were treated with or
without morphine (10
210 M) for 3 h, and then cellular RNA was
subjected to the real-time RT-PCR for mRNA detection. Data are
expressed as mRNA levels in morphine-treated cells (percentage of
control) to those in untreated cells. The results represent the mean 6
SD of three independent experiments. Statistical analysis was per-
formed by Student’s t-test and significance is shown with *P,0.05
(morphine vs control).
doi:10.1371/journal.pone.0031167.g005
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infections and activate IFN pathway signaling [50]. A recent
study showed that purified genomic RNA from HIV induced a
RIG-I dependent type I IFN response [51]. Thus, to suppress
RIG-I expression by morphine should impair intracellular innate
immunity, providing a favorable environment for viral replication.
In addition to its negative effect on RIG-I expression, morphine
also suppressed the expression of IRF-7, the key regulator of type I
IFNs [52]. Similar to type I IFNs, IFN- l1 is also activated by both
IRF-3 and IRF-7 [53]. IRFs not only recognize the elements in the
IFN promoter to modulate the expression of type I IFN genes
selectively, but also regulate the IFN-stimulated response element
(ISRE) in some of IFN-stimulated genes (ISGs), leading to
induction of an antiviral state [54,55]. We were particularly
interested in IRF-3 and IRF-7, as IRF-3 and IRF-7 are the key
regulators of type I IFN gene expression induced by viruses [56].
IRF-7 is the master regulator of type I IFN-dependent immune
response, as it not only induces IFN-a expression, but also
activates many antiviral ISGs [52,57]. Therefore, the suppression
of IRF-7 expression in macrophages by morphine treatment
explains inhibitory effect of morphine on both type I and type III
IFN expression.
APOBEC3 family members are cellular cytidine deaminases
that have the ability to inhibit the mobility of HIV [43,44]. Among
the APOBEC3 family members, APOBEC3G, APOBEC3F and
APOBEC3H have been identified to have the ability to restrict
HIV replication in both CD4
+ T cells and macrophages
[58,59,60,61]. APOBEC3G can either edit the newly synthesized
viral DNA or have an inhibitory effect through lethal editing of
nascent reverse transcripts of the HIV life cycle [62,63,64].
APOBEC3F also encodes an antiretroviral protein that is
selectively packaged into HIV virions and profoundly inhibits
HIV infectivity [65]. APOBEC3B and APOBEC3C have been
shown to act as the potent inhibitors of SIV replication [44]. Thus,
the suppression of several key members of APOBEC3 family in
macrophages by morphine justifies the enhancing effect of
morphine action on HIV or SIV infection and replication.
To further explore the mechanisms involved in morphine-
mediated enhancement of AIDS virus infection of macrophages,
we attempted to determine whether morphine modulates the
expression of the negative regulators of the JAK-STAT signaling
pathway. It is known that the JAK-STAT signaling pathway is the
major pathway for IFN-mediated signaling and activation of gene
expression [66]. IFNs through binding to their specific receptors
activate JAK-STAT pathway, which regulates the expression of
immune system genes [67]. Morphine treatment not only induced
the expression of SOCS-1, SOCS-2 and SOCS-3, but also
enhanced the expression of PIAS-1, PIAS-3, PIAS-X and PIAS-Y,
the potent suppressors of the JAK-STAT signaling cascade
[45,46,68]. These findings support our earlier in vivo investigation,
showing that the heroin users had significantly higher levels of
SOCS and PIAS than the control subjects [69].
Taken together, our study provides compelling experimental
evidence that morphine enhances AIDS virus replication in
macrophages through the modulation of multiple factors in IFN
signaling pathway at both cellular and molecular levels. Although
additional mechanisms might also be involved in the morphine
action on AIDS virus, to suppress the expression of endogenous
IFNs and IFN-inducible antiviral genes should account for much
of morphine-mediated HIV or SIV enhancement in macrophages.
Because morphine exerts a profound and detrimental effects on
Figure 6. Effect of morphine on APOBEC3B/C/F/G/H mRNA
expression. Seven-day-cultured macrophages were treated with or
without morphine (10
210 M) for 3 h, and then cellular RNA was
subjected to the real-time RT-PCR for mRNA detection. Data are
expressed as mRNA levels in morphine-treated cells (percentage of
control) to those in untreated cells. The results represent the mean 6
SD of three independent experiments. Statistical analysis was per-
formed by Student’s t-test and significance is shown with *P,0.05
(morphine versus control).
doi:10.1371/journal.pone.0031167.g006
Figure 7. Effects of morphine on SOCS-1, 2, 3 (A), PIAS-1, 3, X
and Y (B) expression. Seven-day-cultured macrophages were treated
with or without morphine (10
210 M) for 3 h, and cellular RNA was
subjected to the real-time RT-PCR for mRNA detection. Data are
expressed as mRNA levels in morphine-treated cells (percentage of
control) to those in untreated cells. The results represent the mean 6
SD of three independent experiments. Statistical analysis was per-
formed by Student’s t-test and significance is shown with *P,0.05
(morphine versus control).
doi:10.1371/journal.pone.0031167.g007
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or SIV replication in macrophages, it is likely that opiate abuse has
the ability to alter the course of HIV disease progression.
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